Lung cancer after treatment for Hodgkin's lymphoma: a systematic review.

2.50
Hdl Handle:
http://hdl.handle.net/10541/76600
Title:
Lung cancer after treatment for Hodgkin's lymphoma: a systematic review.
Authors:
Lorigan, Paul C ( 0000-0002-8875-2164 ) ; Radford, John A ( 0000-0001-7898-2786 ) ; Howell, Anthony ( 0000-0002-3879-5991 ) ; Thatcher, Nick
Abstract:
Developments in modern chemotherapy and radiotherapy mean that most patients with Hodgkin's lymphoma can now be cured. However, the long-term effects of anticancer treatment include an increased risk of a second malignant disease. We have done a systematic review of studies reporting long-term complications of the treatment of Hodgkin's lymphoma published in English since 1985. These studies show that risk of lung cancer is significantly increased in patients treated for Hodgkin's lymphoma, with a reported mean relative risk of 2.6-7.0 and a significantly increased absolute excess risk. The absolute excess risk increases with time from treatment, for as long as 20-25 years, and is highest in patients treated at age 45 years or older. Both chemotherapy and radiotherapy contribute to the risk, and evidence suggests that the effects are additive. Cigarette smoking seems to multiply the risk associated with both chemotherapy and radiotherapy. In the high-risk group of patients, 50-150 patients per 1000 are expected to develop lung cancer by 10-20 years after treatment. The role of screening in this group of patients has not yet been assessed, but an international study combining CT with genomic and proteomic assessment is planned.
Affiliation:
Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK. paul.lorigan@man.ac.uk
Citation:
Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. 2005, 6 (10):773-9 Lancet Oncol.
Journal:
The Lancet Oncology
Issue Date:
Oct-2005
URI:
http://hdl.handle.net/10541/76600
DOI:
10.1016/S1470-2045(05)70387-9
PubMed ID:
16198983
Type:
Article
Language:
en
ISSN:
1470-2045
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLorigan, Paul C-
dc.contributor.authorRadford, John A-
dc.contributor.authorHowell, Anthony-
dc.contributor.authorThatcher, Nick-
dc.date.accessioned2009-08-06T15:31:23Z-
dc.date.available2009-08-06T15:31:23Z-
dc.date.issued2005-10-
dc.identifier.citationLung cancer after treatment for Hodgkin's lymphoma: a systematic review. 2005, 6 (10):773-9 Lancet Oncol.en
dc.identifier.issn1470-2045-
dc.identifier.pmid16198983-
dc.identifier.doi10.1016/S1470-2045(05)70387-9-
dc.identifier.urihttp://hdl.handle.net/10541/76600-
dc.description.abstractDevelopments in modern chemotherapy and radiotherapy mean that most patients with Hodgkin's lymphoma can now be cured. However, the long-term effects of anticancer treatment include an increased risk of a second malignant disease. We have done a systematic review of studies reporting long-term complications of the treatment of Hodgkin's lymphoma published in English since 1985. These studies show that risk of lung cancer is significantly increased in patients treated for Hodgkin's lymphoma, with a reported mean relative risk of 2.6-7.0 and a significantly increased absolute excess risk. The absolute excess risk increases with time from treatment, for as long as 20-25 years, and is highest in patients treated at age 45 years or older. Both chemotherapy and radiotherapy contribute to the risk, and evidence suggests that the effects are additive. Cigarette smoking seems to multiply the risk associated with both chemotherapy and radiotherapy. In the high-risk group of patients, 50-150 patients per 1000 are expected to develop lung cancer by 10-20 years after treatment. The role of screening in this group of patients has not yet been assessed, but an international study combining CT with genomic and proteomic assessment is planned.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectCanceren
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAge Factors-
dc.subject.meshAntineoplastic Agents-
dc.subject.meshChild-
dc.subject.meshChild, Preschool-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshFemale-
dc.subject.meshFollow-Up Studies-
dc.subject.meshHodgkin Disease-
dc.subject.meshHumans-
dc.subject.meshInfant-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasms, Radiation-Induced-
dc.subject.meshNeoplasms, Second Primary-
dc.subject.meshRisk Factors-
dc.subject.meshSmoking-
dc.titleLung cancer after treatment for Hodgkin's lymphoma: a systematic review.en
dc.typeArticleen
dc.contributor.departmentCancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust, Manchester M20 4BX, UK. paul.lorigan@man.ac.uken
dc.identifier.journalThe Lancet Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.